“ The IIA (Israel Innovation Authority) is responsible for crafting and delivering growth strategies for the Israeli government; in 2018, the Authority started a project to design Israel’s next growth engine in the biotechnology field.

Based on their prior work for Tel Aviv University and their deep knowledge of the biopharma industry and the Israeli ecosystem, we hired Catenion to help us identify local strengths and global industry trends we in Israel might build our strategy on; as a result of this discussion we redirected our thinking away from the mature biotech industry to the emerging field of Bioconvergence.

What exactly is Bio-convergence? The nascent field fuses life sciences with different technologies from mathematics, engineering, and the physical and computational sciences, creating a sum far greater than its parts. Enabled by advances in genomics, gene therapy, DNA sequencing, artificial intelligence, big data, nanotechnology, and synthetic biology, Bio-convergence is paving a holistic path to remarkable innovations in treatment, discovery and treatment.

In a year-long effort, Catenion helped us draft a long-term strategy and implementation plan, which has now become official policy of the IIA; they were crucial to the success of our strategy project and I strongly recommend them to any policy-makers intent on strengthening their local biomedical innovation systems.”